Evidence map›Paper›PMID 33125527›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma.

S T Lee, V Muralidharan, N Tebbutt, P Wong, C Fang, Z Liu, H Gan, J Sachinidis, K Pathmaraj, C Christophi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

S T LeeDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. szeting.lee@austin.org.au.ORCID http://orcid.org/0000-0001-8641-456X
V MuralidharanDepartment of Surgery, Austin Health, Melbourne, Australia.
N TebbuttDepartment of Surgery, The University of Melbourne, Austin Health, Melbourne, Australia.
P WongDepartment of Surgery, Austin Health, Melbourne, Australia.
C FangTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.
Z LiuTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.
H GanTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.
J SachinidisDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
K PathmarajDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
C ChristophiDepartment of Surgery, Austin Health, Melbourne, Australia.
A M ScottDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
The University of Melbourne · AUAustin Health · AUOlivia Newton-John Cancer Wellness & Research Centre · AULa Trobe University · AU

Funding

National Health and Medical Research Council 1084178National Health and Medical Research Council (AU) 1092788
6 · The paper itself

Abstract

purposeHypoxia is associated with aggressive tumour behaviour and can influence response to systemic therapy and radiotherapy. The prevalence of hypoxia in metastatic colorectal cancer is poorly understood, and the relationship of hypoxia to patient outcomes has not been clearly established. The aims of the study were to evaluate hypoxia in metastatic colorectal cancer with [

methodsPatients with metastatic colorectal cancer received routine staging investigations and both [

resultsA total of 40 patients were recruited into the trial. [

conclusion[

Indexed as

Colorectal NeoplasmsHead and Neck NeoplasmsBiomarkersFluorodeoxyglucose F18HumansHypoxiaMisonidazolePositron-Emission TomographyPrevalenceRadiopharmaceuticalsBiomarkersFluorodeoxyglucose F18MisonidazoleRadiopharmaceuticalsFMISO PETHypoxiaMetastatic colorectal carcinomaOsteopontinVEGF

Identifiers

PMID33125527
OpenAlexW3095749605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.